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Objective: The aim of this study was to assess the potential risk of gadobutrol-
enhanced magnetic resonance imaging (MRI) in patients with moderate to severe
renal impairment for the development of nephrogenic systemic fibrosis (NSF).
Materials andMethods:We performed a prospective, international, multicenter,
open-label study in 55 centers. Patients with moderate to severe renal impairment
scheduled for any gadobutrol-enhancedMRI were included. All patients received
a single intravenous bolus injection of gadobutrol at a dose of 0.1 mmol/kg body
weight. The primary target variable was the number of patients who develop NSF
within a 2-year follow-up period.
Results: A total of 908 patients were enrolled, including 586 with moderate and
284 with severe renal impairment who are at highest risk for developing NSF. The
mean time since renal disease diagnosis was 1.83 and 5.49 years in the moderate
and severe renal impairment cohort, respectively. Overall, 184 patients (20.3%)
underwent further contrast-enhanced MRI with other gadolinium-based contrast
agents within the 2-year follow-up. No patient developed symptoms conclusive
of NSF.
Conclusions: No safety concerns with gadobutrol in patients with moderate to
severe renal impairment were identified. There were no NSF cases.
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back to 1997.1 Nephrogenic systemic fibrosis is a rare disease, but
it can be severe. Indicative clinical symptoms are a thickening and
hardening of the skin due to proliferation of connective tissue, which
can ultimately lead to contractures and joint immobility. Other or-
gans, for example, heart, lungs, liver, and muscles, may be affected
in later stages. Disease development can last from a couple of weeks
to several months or even years. Most cases of NSF have been seen
in patients with severe renal impairment (estimated glomerular fil-
tration rate [eGFR], <30 mL/min per 1.73 m2) and in patients with
acute renal injury. At present, the etiology of NSF is not completely
elucidated. A potential link between NSF and the application of
gadolinium-based contrast agents (GBCAs) was first described by
Grobner et al in 2006.2 In addition, other triggers such as metabolic ac-
idosis,2 vascular surgery,2 treatment with erythropoietin,3 or systemic
inflammation have been suggested to cause development of NSF. To es-
tablish a definitive diagnosis, a histopathological confirmation of a skin
biopsy specimen is mandatory.4
The risk of a GBCA to trigger NSF seems to be related to the sta-
bility of the agent. Thus, nonionic linear GBCAs are more likely to trig-
ger NSF than ionic linear agents both of which are distinctly more likely
to trigger the disease than the macrocyclic agents in patients with re-
duced renal function.5
Gadobutrol is a gadolinium (Gd)-based contrast agent for mag-
netic resonance imaging (MRI). It is approved for a wide range of clin-
ical indications covering the age range from full-term newborns to
adults. However, approved indications and age ranges are country-
specific. In Europe, gadobutrol is approved for the entire spectrum
of indications in all age groups.6
Gadobutrol (Gadovist, Gadavist; Bayer Pharma AG, D-51368
Leverkusen, Germany) is a second-generation nonionic, multipurpose,
extracellular, macrocyclic GBCA7,8 provided in a 1 molar concentra-
tion. In addition to its unique double concentration, gadobutrol features
the highest relaxivity of all macrocyclic GBCAs.7,9,10 As a macrocyclic
contrast agent, gadobutrol provides high chelate stability with substan-
tially less—if any—in vivo release of Gd ions as opposed to linear
GBCAs.11 The release of Gd ions has been linked to an increased
risk of NSF in patients with impaired renal function.12,13 Because
of these characteristics, gadobutrol was categorized as a low-risk
GBCA for development of NSF by several medical organisations4,13
and authorities.5,14,15
The recommended standard dose of gadobutrol for intravenous
injection is 0.1 mmol/kg body weight (bw), with doses up to 0.3
mmol/kg bw approved for specific indications in adults. The efficacy
and safety of gadobutrol have been demonstrated in numerous clinical
studies in adults and children, including full-term newborns.7,16–21
Following an FDA postmarketing requirement to all manufac-
turers of GBCAs in the United States in December 2009,22 we voluntar-
ily initiated this study on gadobutrol adhering to the FDA's stipulations.
The study title was “Prospective non-randomized cohort study (open-www.investigativeradiology.com 55
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administration of Gadovist in patients with moderate to severe renal
impairment for the development of NSF based on diagnostically
specific clinical and histopathologic information” (EudraCT no.
2008-004496-22, NCT00828737). The initiation of this “GRIP”
study (Gadobutrol in Renally Impaired Patients) was a preemptive mea-
sure. In 2009, gadobutrol was not yet approved in the United States, but
Bayer planned its market introduction in the near future and there-
fore decided to voluntarily perform this study with gadobutrol follow-
ing the specific FDA stipulations.
MATERIALS AND METHODS
Study Design
GRIP was a prospective, nonrandomized, open-label phase IV
study performed in 55 centers in 9 countries (Germany [18 centers],
Italy [10], Spain [3], Austria [6], Switzerland [1], Canada [5], Australia
[2], South Korea [8], and Thailand [2]). The study period lasted from
December 2008 to January 2015. The primary objective was to assess
the magnitude of potential risk of developing NSF after gadobutrol ad-
ministration in patients with moderate to severe renal impairment.
Study Population
The study population consisted of patients with moderate to se-
vere renal impairment scheduled for gadobutrol-enhanced MRI within
the approved indications and dose. The study was conducted in accor-
dance with all international and local guidelines and laws stated by
the involved institutional review boards. Oral and written informed con-
sent was obtained before each examination.
The classification of cohorts based on the degree of renal im-
pairment was already described by Lauenstein et al23 in a study on
gadoxetate disodium. The identical classification was used in the
present study. The definitions in brief are as follows: “severe” renal
impairment was defined by an eGFR of <30 mL/min per 1.73 m2 or
dialysis. “Moderate” renal impairment was defined as an eGFR be-
tween ≥30 and ≤59 mL/min per 1.73 m2. However, renal status
was tested twice—first during screening within 6 weeks before the
gadobutrol injection at the local laboratory and second at baseline
(ie, 48 hours before gadobutrol administration) at a central labora-
tory. As a result, 2 additional cohorts were defined post hoc: (1) an
“extended moderate” renal impairment cohort (presenting an eGFR
≤59 mL/min per 1.73 m2 at screening, but >59 and ≤65 mL/min per
1.73 m2 at baseline) and (2) a “mild” renal impairment cohort (pre-
senting an eGFR ≤59 mL/min per 1.73 m2 at screening, but an eGFR
>65 mL/min per 1.73 m2 at baseline) (Table 1).
Treatment
All patients received a single intravenous bolus injection of
0.1 mmol/kg (0.1 mL/kg) bw gadobutrol followed by a 20 mL saline
flush in the framework of the clinical routine diagnostic workup.
Gadobutrol is marketed in all participating countries and was pro-
vided by the local hospital pharmacies.TABLE 1. Classification of Study Cohorts
Renal Impairment Mild Ex
Screening/informed consent (6 wk before MRI) ≤59
Baseline 48 h before MRI >65
Renal impairment at screening and baseline according to eGFR (mL/min per 1.73
MRI indicates magnetic resonance imaging.
56 www.investigativeradiology.comTarget Variables
The primary target variable was defined as the number of pa-
tients with moderate to severe renal impairment who developed NSF
during the 2-year follow-up period.23 Nephrogenic systemic fibrosis
was defined as described by Girardi et al.4 Secondary target variables
included (1) number of patients without biopsy but who later developed
NSF-like symptoms based solely on the clinical score by Girardi et al4;
and (2) number and characteristics of adverse events reported in associ-
ation with the administration of gadobutrol.
Study Procedures
The study procedures were identical to those described by
Lauenstein et al.23 Our focus was to establish a standardized diag-
nostic workup and data collection for potential NSF cases in the
daily clinical routine.
Blood sampling to assess eGFRwas performed twice—first dur-
ing screening within 6 weeks before the MRI examination at the local
laboratory and second at baseline (ie, 48 hours before gadobutrol ad-
ministration) at a central laboratory.
After gadobutrol administration, patients were followed for
clinical examination and review of source documents after 12 and
24 months. In addition, telephone interviews were performed 1, 3,
6, and 18 months after gadobutrol administration by health care pro-
fessionals who were trained on the study protocol and specifically
for identification of clinical signs of NSF.
Any skin finding with the faintest suspicion of NSF was clini-
cally assessed. In cases where a biopsy was taken, a histopathological
assessment had to be performed. Here, the Girardi criteria had to be ap-
plied.4 This strategy ensured that the risk tomiss a potential case of NSF
was minimized.
Statistics and Sample Size
Descriptive statistics including sample size, mean, standard devi-
ation, minimum, and maximum were calculated for quantitative vari-
ables. Frequency counts and percentages by category were generated
for qualitative data. Summaries are presented by renal status cohort
(mild, extended moderate, moderate, and severe renal impairment)
and overall study population.23 Nephrogenic systemic fibrosis out-
come had to be reported individually.
The Joint Meeting of the Cardiovascular and Renal Drugs and
Drug Safety and Risk Management Advisory Committee of the FDA
(December 8, 200922) stipulated a 2-year observational study for
all GBCAs approved in the United States to assess the likelihood of
NSF development. The FDA proposed a sample size of 1000 patients,
consisting of 600 patients with moderate and 400 patients with severe
renal impairment.
The FDA's sample size suggestion was based on a retrospective
study of 370 patients with severe renal insufficiency who received
gadodiamide. The estimated risk for development of NSF was approxi-
mately 4%.24On June 2, 2011, the FDA released the pharmaceutical com-
panies manufacturing GBCAs from completing study enrollment but the
full 2-year follow-up was required for all patients already enrolled.25Moderate
Severe (+ Dialysis)tended moderate Moderate
≤59 ≤59 ≤59
>59 and ≤65 ≥30 and ≤59 <30
m2) from Lauenstein et al.23
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Demographic and Baseline Characteristics by Degree of Renal Impairment (FAS)
Renal Impairment Mild, n = 38*
Moderate Severe,
n = 201*
Severe + Dialysis,
n = 83
Overall,
n = 908*Extended Moderate, n = 46 Moderate, n = 540*
Age, y
Mean ± SD 61.8 ± 13.9 67.2 ± 11.6 68.0 ± 12.0 66.8 ± 12.2 59.8 ± 13.8 66.7 ± 12.5
Age group
<65 y 21 (55.3) 14 (30.4) 177 (32.8) 74 (36.8) 46 (55.4) 332 (36.6)
≥65 y 17 (44.7) 32 (69.6) 363 (67.2) 127 (63.2) 37 (44.6) 576 (63.4)
Sex, n (%)
Male 24 (63.2) 28 (60.9) 361 (66.9) 126 (62.7) 52 (62.7) 591 (65.1)
Female 14 (36.8) 18 (39.1) 179 (33.1) 75 (37.3) 31 (37.3) 317 (34.9)
Ethnic group
White 35 (92.1) 32 (69.6) 478 (88.5) 182 (90.5) 64 (77.1) 791 (87.1)
Black 0 0 2 (0.4) 1 (0.5) 0 3 (0.3)
Hispanic 0 0 2 (0.4) 1 (0.5) 0 3 (0.3)
Asian 3 (7.9) 12 (26.1) 51 (9.4) 13 (6.5) 16 (19.3) 95 (10.5)
Other 0 2 (4.3) 7 (1.3) 4 (2.0) 3 (3.6) 16 (1.8)
Weight, kg
Mean ± SD 76.8 ± 18.0 73.6 ± 17.1 78.3 ± 16.8 75.5 ± 15.9 70.4 ± 15.3 76.7 ± 16.7
*Weight: mild cohort, n = 37; moderate cohort, n = 539; severe, n = 200; total, n = 905.
FAS indicates full analysis set; SD, standard deviation.
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tocol and concluded enrollment by December 31, 2012, with 927 of the
1000 originally planned patients enrolled. All patients were included in
the 2-year safety follow-up.
RESULTS
The study enrolled 927 patients. Nine hundred eight patients re-
ceived gadobutrol and completed the MRI examination and were in-
cluded in the analysis: 284 with severe, 540 with moderate, 46 with
extended moderate, and 38 with mild renal impairment (Table 2). A to-
tal of 581 patients (64.0%) completed the 24 months' follow-up.
The mean age was 66.7 years (range, 19–94 years) with 63.4%
of patients being 65 years or older. Almost two thirds of the patients
were male, and 87.1% were white. There were no apparent differences
in the degree of renal impairment among the various demographic
subgroups (Table 2).
The period from initial diagnosis of renal disease increased
with the severity of renal impairment and ranged from 1.83 years
in the extended moderate renal impairment cohort to 5.49 years in
the severe renal impairment cohort (overall range less than 0.1 to
60.4 years). Hypertension and diabetes were the most frequently re-
ported causes of renal disease, with incidence rates of 58.5% and
31.9%, respectively. Eighty-three patients (9.1%) were dependent
on dialysis and thus assigned to the severe renal impairment cohort.
Vascular injuries were reported by 386 patients (42.5%), with the
majority in the cohort with moderate (43.0%) and severe (46.1%) re-
nal impairment. Seventy patients (7.7%) had a history of organ
transplant surgery, all in the moderate and severe renal impairment
cohort (Table 3).
Overall, 228 patients (25.1%) underwent contrast-enhanced
MRI with another GBCA within 12 months before the inclusion in
the study start or in the follow-up period. Ninety-seven patients
(10.7%) of the 908 were exposed to gadobutrol before the inclusion
in the study, and 184 patients (20.3%) received additional different
GBCAs during follow-up, that is, after gadobutrol administration
at baseline. The number of GBCA administrations ranged from 1
(114 patients, 12.6%) to >5 (14 patients, 1.5%) (Table 4). Two of© 2016 Wolters Kluwer Health, Inc. All rights reserved.the patients with more than 5 additional injections of GBCAs had re-
ceived these injections at baseline, and 6 patients received more than
5 additional injections during follow-up.
During the period immediately after gadobutrol administration
and before leaving the MRI facility, 3 patients (0.3%) experienced
drug-related adverse events (AEs): urticaria, retching, and rash. None
of these AEs were considered serious or life threatening.
During the 24-month follow-up, AE reporting focused on
skin-related findings and other findings suggestive of NSF. Patients
with mild renal impairment were not included in the follow-up. Dur-
ing this follow-up, a total of 135 patients (14.9%) reported skin-
related findings. The frequency was similar within the 3 cohorts of
renal impairment. Four patients (0.4%) (3 in the moderate, 1 in the
severe renal impairment cohort) suffered a rash, but no patient devel-
oped symptoms indicative of NSF.
No serious adverse events occurred between the date of in-
formed consent and the date the patient left the MRI facility on the
day of gadobutrol injection or during the follow-up. However,
166 patients died during the follow-up period. The frequency of
deaths was related to the severity of renal impairment, with 10.9%,
18.1%, and 22.2% of patients in the cohorts with extended moderate,
moderate, and severe renal impairment, respectively. Progression of
renal disease was the most frequent cause of death. None of the pa-
tients with skin-related findings died.
DISCUSSION
Following the FDA's postmarketing requirement for all
US-approved GBCAs,22 we voluntarily initiated this study on gad-
obutrol adhering to the FDA's proposed study design. This was a pre-
emptive measure as we expected gadobutrol to be approved in the
United States shortly. No case of NSF was detected in our study.
To the best of our knowledge, this is the first publication of
prospective data on the incidence of NSF after gadobutrol adminis-
tration. As of May 2016, several similar studies on other GBCAs
have been reported. One study by Lauenstein et al,23 investigated
gadoxetate disodium in 357 patients. No case of NSF was recor-
ded. Another recent study by Amet et al26 investigated the risk ofwww.investigativeradiology.com 57
TABLE 3. History of Renal Disease by Degree of Renal Impairment (FAS)
Renal Impairment Mild, n = 38 Moderate Severe + Dialysis, n = 284 Overall, n = 908
Extended Moderate, n = 46 Moderate, n = 540
Years since renal diagnosis
n* 13 21 152 50 236
Mean ± SD 2.00 ± 2.3 1.83 ± 3.5 1.99 ± 4.73 5.49 ± 10.93 2.72 ± 6.53
Cause of renal disease, n (%)
Diabetes 8 (21.1) 9 (19.6) 166 (30.7) 107 (37.7) 290 (31.9)
Glomerulonephritis 0 0 8 (1.5) 23 (8.1) 31 (3.4)
Collagen disease 0 0 3 (0.6) 7 (2.5) 10 (1.1)
Hypertension 22 (57.9) 22 (47.8) 310 (57.4) 177 (62.3) 531 (58.5)
Polycystic kidney disease 0 0 21 (3.9) 22 (7.7) 43 (4.7)
Other 21 (55.3) 30 (65.2) 280 (51.9) 112 (39.4) 443 (48.8)
Receiving dialysis, n (%)
Any 0 0 0 83 (29.2) 83 (9.1)
Peritoneal dialysis 0 0 0 9 (3.2) 9 (1.0)
Hemodialysis 0 0 0 74 (26.1) 74 (8.1)
Vascular injuries, n (%)†
Any 9 (23.7) 14 (30.4) 232 (43.0) 131 (46.1) 386 (42.5)
Shunt surgery/repair 0 4 (8.7) 63 (11.7) 66 (23.2) 133 (14.6)
Organ transplant surgery 0 0 38 (7.0) 32 (11.3) 70 (7.7)
Thrombotic events 7 (18.4) 3 (6.5) 72 (13.3) 41 (14.4) 123 (13.5)
Other surgeries 4 (10.5) 8 (17.4) 98 (18.1) 47 (16.5) 157 (17.3)
Other 3 (7.9) 7 (15.2) 67 (12.4) 50 (17.6) 127 (14.0)
*Number of patients with information available.
†Patients reporting more than 1 injury per injury type were counted only once for each type.
FAS indicates full analysis set; SD, standard deviation.
Michaely et al Investigative Radiology • Volume 52, Number 1, January 2017gadoteric acid in 255 patients on dialysis with no findings of NSF. In
addition, Soulez et al27 reported 2 prospective 2-year studies in
534 patients with either stage 3 chronic kidney disease (CKD) or
stage 4 to 5 CKD. No signs or symptoms of NSF were reported after
administration of gadobenate dimeglumine or gadoteridol. Smorodinsky
et al28 retrospectively evaluated 1167 patients with chronic liverTABLE 4. Patients With and Number of GBCA Injections From 12 Month
Follow-up (FAS)
Renal Impairment Mild, n = 38 Moderate
Extended Moderate, n = 46
No. patients with GBCA injections, n (%)
Overall* 4 (10.5) 15 (32.6)
Before study start† 4 (10.5) 4 (8.7)
During follow-up 0 13 (28.3)
Total no. GBCA injections in addition to the study injection, n (%)‡
1 2 (5.3) 4 (8.7)
2 0 5 (10.9)
3 1 (2.6) 4 (8.7)
4 0 0
5 0 0
>5 1 (2.6) 2 (4.3)
*Includes patients that had GBCA injections before study start as well as during f
†Only gadobutrol was allowed.
‡Includes all GBCA injections from 12 months before and during follow-up.
GBCA indicates gadolinium-based contrast agent; FAS, full analysis set.
58 www.investigativeradiology.comdisease where 72% also had some degree of renal insufficiency.
They did not report any case of NSF. The GBCAs applied in that
study were gadobenate dimeglumine, gadoversetamide, gadopentetate
dimeglumine, gadodiamide, and gadoteridol.
Our study population consisted of 908 patients. A total of
284 patients had severe, and 586 had moderate renal impairment,s Before Study Start (Gadobutrol Administration) and During
Severe + Dialysis, n = 284 Overall, n = 908
Moderate, n = 540
159 (29.4) 50 (17.6) 228 (25.1)
72 (13.3) 17 (6.0) 97 (10.7)
131 (24.3) 40 (14.1) 184 (20.3)
74 (13.7) 34 (12.0) 114 (12.6)
39 (7.2) 6 (2.1) 50 (5.5)
15 (2.8) 4 (1.4) 24 (2.6)
13 (2.4) 3 (1.1) 16 (1.8)
9 (1.7) 1 (0.4) 10 (1.1)
9 (1.7) 2 (0.7) 14 (1.5)
ollow-up.
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Investigative Radiology • Volume 52, Number 1, January 2017 NSF Risk After Gadobutrol-Enhanced MRIconsistent with the target population requested by the FDA. In a
number of patients, the 2 eGFR determinations (one at screening
and one immediately before the MRI examination at baseline) re-
sulted in different patient classifications based on the cutoff values
for mild, moderate, or severe renal impairment. Some patients who
originally fulfilled the criterion for moderate renal impairment at
the time of screening actually showed improved renal function at
the time of contrast injection.23 To reflect a worst-case scenario,
we subsumed those patients still in the category of moderate renal
impairment and performed a 2-year follow-up. However, to be fully
transparent, we reported these patients in a subgroup as “extended
moderate” (Table 1). For the 38 patients in the mild renal disease
group an elevated NSF risk has not been established,29 so follow-up
was waived according to protocol.
Interestingly, many patients did not only receive gadobutrol
during the study period. A total of 228 patients (25.1%) received
other, additional GBCA administrations 12 months before study
start and/or during the 2-year follow-up. Being fully aware that this
might confound/harm our primary objective, we still decided to in-
clude all these patients in our analysis. Thus, we chose the most con-
servative approach and report the full-analysis data set that includes
all patients who have received at least 1 dose of gadobutrol. There-
fore, we feel confident that our study population reflects the clinical
reality of patients with renal impairment. In addition, as the increas-
ing number and dose of GBCA administrations is postulated to in-
crease the likelihood of triggering NSF development, it appears
reassuring that even in patients with exposure to multiple GBCAs
no case of NSF was observed.
In our study cohort, most patients had renal disease caused by
hypertension (58.5%) or diabetes (31.9%), both being very common
in the modern Western world.30,31
No new safety concerns came up during the study period. No
serious adverse events occurred between the date of informed con-
sent and the date the patient left the MRI facility or on the day of
gadobutrol injection or during the follow-up period. Progression
of renal disease was the most frequent cause of death. Our results
are in accordance with other reports on gadobutrol use in patients
with renal impairment. Even in patients with chronic renal impair-
ment, including hemodialysis, gadobutrol can safely be applied at
doses up to 0.3 mmol/kg,32 providing evidence that gadobutrol is
safe in patients with renal impairment.33
Today, gadobutrol is approved in more than 100 countries world-
wide, including the European Union, Switzerland, Australia, United
States, Canada, Japan, and China. Since its introduction to the market
in February 1998 until December 2015, the cumulative patient exposure
is estimated to be more than 29 million patients.21 As of May 2016,
the pharmacovigilance department of Bayer Pharma AG has re-
ceived 3 single-agent reports, so-called unconfounded reports, for
gadobutrol consistent with the clinicohistopathological definition
of NSF. This classification was rigorously performed after a most
stringent and conservative approach according to the criteria by
Girardi et al.4 In case clinicopathological criteria or laboratory parame-
ters reached a score of ≥1, Bayer always assumed a worst-case sce-
nario.21 Bayer continues to follow a policy of total transparency
regarding NSF, with expedited case reporting to health authorities
all over the world.21
Finally, it is important to note that the FDA34 and the European
Medicines Agency35 have defined risk categories for GBCAs. Gadobu-
trol, as well as the 2 other macrocyclic GBCAs, gadoterate meglumine
and gadoteridol, belong to the class with the lowest risk for NSF devel-
opment. Also, the European Society of Urogenital Radiology (ESUR)
followed those categories in their recommendations.5 The ESUR classi-
fied macrocyclic agents as “low risk” but still recommends that they
should be used with caution in patients with CKD 4 and 5 (GFR
<30 mL/min per 1.73 m2), and there should be at least 7 days© 2016 Wolters Kluwer Health, Inc. All rights reserved.between 2 injections. Furthermore, pregnant women should only
be imaged with contrast-enhanced MRI if the expected diagnostic
information is essential. However, laboratory testing of renal func-
tion (eGFR) is not mandatory, and the ESUR Contrast Medium
Safety Committee guidelines state that a questionnaire on renal
function should be sufficient.5 On May 23, 2007, the FDAmandated
a boxed warning on the product labeling of all GBCAs.36
There are several limitations to our study that need to be taken
into account when interpreting the results. Although we followed the
FDA's stipulations,22 the sample size must be considered as a major
limitation. In a letter dated June 2, 2011, the FDA stated that “the es-
timate of the incidence of NSF in patients with renal insufficiency,
based on postmarketing surveillance reports, is lower than the orig-
inal literature-based estimate.” Therefore, the trial's sample size
became inadequate to assess the magnitude of NSF risk of GBCAs
in patients with renal insufficiency.25 We stopped enrollment on
December 31, 2012, but still conducted the 2-year follow-up.
The second limitation is related to the concomitant applica-
tion of other GBCAs during the course of the study. However, we
consider it reassuring that none of these patients developed signs
of NSF.
Because the FDA asked all manufacturers of GBCAs marketed
in the United States to run similar studies, further reports on other
GBCAs are expected to be published soon. Once all results are avail-
able, we suggest that a final assessment of the impact of GBCA admin-
istration on NSF development should be performed.
CONCLUSIONS
Gadobutrol in patients with moderate to severe renal impairment
did not raise any clinically significant safety signals. No NSF cases
were observed.
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